Friday, July 10, 2026

pharma · Hypoparathyroidism (HP) in Adults · Chronic hypoparathyroidism

Ascendis Pharma

Ascendis Pharma Bone is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypoparathyroidism (HP) in Adults, Chronic hypoparathyroidism. NovaPharmaNews links 2 clinical program(s), 0 drug

Palo Alto, USA HQ
2010 Founded
5 Employees
EMA registrant Type
Company details
Status
Public
HQ
Palo Alto, USA
Founded
2010
Employees
5
Programs
2
Drugs
3
Patents
12
Clinical program

TransCon PTH

Phase 2 · small molecule · Hypoparathyroidism (HP) in Adults

TransCon PTH for Hypoparathyroidism (HP) in Adults is a Phase 2 program (small_molecule) at Ascendis Pharma Bone Diseases A/S with 1 ClinicalTrials.gov record(s).

Internal code TransCon PTH TCP-201

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Ascendis Pharma Bone Diseases A/S
Phase
Phase 2
Modality
small_molecule
Indication
Hypoparathyroidism (HP) in Adults
Status
active
Trials
1

Clinical trials